BioXcel Therapeutics, Inc.
BTAI
Health Care
2
exclusion reasons
1 theme
BioXcel Therapeutics, Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
BioXcel Therapeutics is a clinical-stage biopharmaceutical company whose core business model relies on animal testing to develop and gain regulatory approval for its drug candidates. The company’s pipeline, including its lead investigational therapies, requires preclinical safety and efficacy studies conducted on animals as a standard phase of pharmaceutical development.
A shareholder lawsuit filed in 2023 (Hills et al v. BioXcel Therapeutics, Inc. et al) includes causes of action under Animal & Dog Law, indicating legal scrutiny of the company's animal testing practices. Furthermore, BioXcel’s clinical trials have faced regulatory challenges, including an FDA inspection that concluded with a Voluntary Action Indicated status in 2025, suggesting procedural deficiencies in its operations. The company has also utilized contract research organizations to conduct trials, a common practice that outsources animal testing activities.
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company whose drug development pipeline relies on animal testing to meet regulatory requirements. The company's SEC filings routinely cite the completion of preclinical animal studies as a necessary step in its research and development process for neurological and immuno-oncology therapeutics. This reliance is explicit in multiple annual and quarterly reports, which list "animal studies" alongside laboratory tests as part of standard development activities.
Published research related to the company's drug candidates, such as a 2025 ascending-dose study, references "various in vivo animal experiments" conducted to assess pharmacokinetics and distribution. As a pharmaceutical company seeking FDA approval for novel compounds, BioXcel Therapeutics commissions and relies on animal data to support its Investigational New Drug applications, a practice that places it within the animal_testing exclusion category. The available evidence from regulatory filings and scientific publications confirms animal testing is integral to its business model, though specific details on the scale or nature of the animal use are not disclosed in the gathered sources.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.